INM
InMed Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.75
+4.17%Nov 3, 2026, 12:30 UTC
InMed Pharmaceuticals reported financial results for its first quarter of fiscal 2027, ended September 30, 2026.
Source:Nov 2, 2026, 21:15 UTC
InMed Pharmaceuticals announced a proposed consolidation of its common shares at a ratio of one post-consolidation share for every ten pre-consolidation shares, subject to shareholder approval at its November 4, 2026 meeting.
Source:Sep 18, 2026, 21:17 UTC
InMed Pharmaceuticals Inc. received a NASDAQ notice dated September 16, 2026 for failing to comply with the minimum shareholders' equity requirement under Rule 5550(b)(1), and intends to submit a compliance plan by November 2, 2026.
Sep 9, 2026, 20:30 UTC
InMed Pharmaceuticals reported its financial results for the fiscal year ended June 30, 2026.
Source:Jul 6, 2026, 22:20 UTC
InMed Pharmaceuticals and Mentari Therapeutics amended their merger agreement and filed a registration statement on Form S-4 with the SEC for their proposed all-stock merger.
Source:Jun 4, 2026, 21:00 UTC
InMed Pharmaceuticals received notice from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing.